The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 14: 2027 - 2030

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.14.021

Reviews

Research progress on the regulation of intestinal flora on glioma

  • Kexin XI ,
  • Yuqi ZHAO ,
  • Xiaoting XIE ,
  • Yuntao LU ,
  • Hongying FAN ,
  • Xiaoyan. HE
Expand
  • BSL?3 Laboratory，Guangdong Key Laboratory of Tropical Diseases，Southern Medical University，Guangzhou 510515，China

Received date: 2023-08-22

  Online published: 2024-07-15

Fold

Abstract

Glioma is the most common primary tumor of the brain， accounting for 81 % of central nervous system （CNS） malignant tumors. The degree of malignancy is high， and the current treatment methods are limited. In recent years， with the in-depth study of intestinal flora and brain-gut axis， it has been found that the diversity of gut microbiota plays an important role in the regulation of glioma. The mechanism is that the intestinal flora affects the development of glioma through the role of immune regulation and metabolites. In addition， it has been confirmed that there is a certain correlation between some probiotics and glioma， which provides a new application prospect for the treatment of glioma. This paper discusses the main intestinal bacteria that regulate gliomas as well as the role and regulatory mechanisms of intestinal flora in the development of gliomas， and provides ideas for the discovery of new targets for glioma treatment and further improvement of treatment options.

Key words： intestinal flora; glioma; brain-gut axis

Cite this article

Kexin XI , Yuqi ZHAO , Xiaoting XIE , Yuntao LU , Hongying FAN , Xiaoyan. HE . Research progress on the regulation of intestinal flora on glioma[J]. The Journal of Practical Medicine, 2024 , 40(14) : 2027 -2030 . DOI: 10.3969/j.issn.1006-5725.2024.14.021

References

1 XU S， TANG L， LI X， et al. Immunotherapy for glioma：current management and future application［J］. Cancer Lett， 2020， 476：1-12. doi:10.1016/j.canlet.2020.02.002
2 GUSYATINER O， HEGI M E. Glioma epigenetics： From subclassification to novel treatment options［J］. Semin Cancer Biol， 2018， 51：50-58. doi:10.1016/j.semcancer.2017.11.010
3 ESLAHI M， DANA P M， ASEMI Z， et al. The effects of chitosan-based materials on glioma： Recent advances in its applications for diagnosis and treatment［J］. Int J Biol Macromol， 2021，168：124-129. doi:10.1016/j.ijbiomac.2020.11.180
4 姜海啸，曾巍，张恒柱，等. 肠道菌群及其代谢产物在胶质瘤中的调控机制研究进展［J］. 肿瘤预防与治疗， 2022，35（4）：388-392. doi:10.3969/j.issn.1674-0904.2022.04.013
5 MA P J， WANG M M， WANG Y. Gut microbiota： A new insight into lung diseases［J］. Biomed Pharmacother， 2022，155：113810. doi:10.1016/j.biopha.2022.113810
6 BIDELL M R， HOBBS A L V， LODISE T P. Gut microbiome health and dysbiosis： A clinical primer［J］. Pharmacotherapy， 2022， 42（11）：849-857. doi:10.1002/phar.2731
7 QUAGLIO A E V， GRILLO T G， DE OLIVEIRA E C S， et al. Gut microbiota， inflammatory bowel disease and colorectal cancer［J］. World J Gastroenterol， 2022， 28（30）：4053-4060. doi:10.3748/wjg.v28.i30.4053
8 LONG Y， TANG L， ZHOU Y， et al. Causal relationship between gut microbiota and cancers： a two-sample Mendelian randomisation study［J］. BMC Med， 2023，21（1）：66. doi:10.1186/s12916-023-02761-6
9 MANOS J. The human microbiome in disease and pathology［J］. APMIS， 2022，130（12）：690-705. doi:10.1111/apm.13225
10 OSADCHIY V， MARTIN C R， MAYER E A. The Gut-Brain Axis and the Microbiome： Mechanisms and Clinical Implications［J］. Clin Gastroenterol Hepatol， 2019， 17（2）：322-332. doi:10.1016/j.cgh.2018.10.002
11 YIN Y， GUO Q， ZHOU X， et al. Role of brain-gut-muscle axis in human health and energy homeostasis［J］. Front Nutr， 2022， 9：947033. doi:10.3389/fnut.2022.947033
12 FLANNONE L F， GOMEZ-EGUILAZ M， DE CARO C. Gut microbiota manipulation as an epilepsy treatment［J］. Neurobiol Dis， 2022，174：105897. doi:10.1016/j.nbd.2022.105897
13 LYU Y， YANG H， CHEN L. Metabolic regulation on the immune environment of glioma through gut microbiota［J］. Semin Cancer Biol， 2022， 86（Pt 2）：990-997. doi:10.1016/j.semcancer.2021.05.005
14 刘树昕，吴爱娟，甄妮，等. 广谱抑菌乳酸菌的筛选及其细菌素相关基因分析［J］. 食品科学， 2020，41（6）：101-107.
15 DONO A， NICKLES J， RODRIGUEZ-ARMENDARIZ A G， et al. Glioma and the gut-brain axis： opportunities and future perspectives［J］. Neurooncol Adv， 2022，4（1）：vdac054. doi:10.1093/noajnl/vdac054
16 HOU X， DU H， DENG Y， et al. Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma［J］. J Transl Med， 2023，21（1）：198. doi:10.1186/s12967-023-04042-5
17 PATRIZZ A， DONO A， ZOROFCHIAN S， et al. Glioma and temozolomide induced alterations in gut microbiome［J］. Sci Rep， 2020，10（1）：21002. doi:10.1038/s41598-020-77919-w
18 D'AlESSANDRO G， LAURO C， QUAGLIO D， et al. Neuro-Signals from Gut Microbiota： Perspectives for Brain Glioma［J］. Cancers （Basel）， 2021，13（11）：2810. doi:10.3390/cancers13112810
19 DONO A， NICKLES J， RODRIGUEZ-ARMENDARIZ A G， et al. Glioma and the gut-brain axis： opportunities and future perspectives［J］. Neurooncol Adv， 2022，4（1）：vdac054. doi:10.1093/noajnl/vdac054
20 FAN Y， SU Q， CHEN J， et al. Gut Microbiome Alterations Affect Glioma Development and Foxp3 Expression in Tumor Microenvironment in Mice［J］. Front Onco， 2022，12：836953. doi:10.3389/fonc.2022.836953
21 YOSHIKAWA S， TANIGUCHIi K， SAWAMURA H， et al. Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma［J］. Explor Target Antitumor Ther， 2022，3（6）：817-827.
22 GOPALAKRISHNAN V， HELMINK B A， SPENCER C N， et al. The Influence of the Gut Microbiome on Cancer， Immunity， and Cancer Immunotherapy［J］. Cancer Cell， 2018，33（4）：570-580. doi:10.1016/j.ccell.2018.03.015
23 ZHU J， SU J. Alterations of the Gut Microbiome in Recurrent Malignant Gliomas Patients Received Bevacizumab and Temozolomide Combination Treatment and Temozolomide Monotherapy［J］. Indian J Microbiol， 2022，62（1）：23-31. doi:10.1007/s12088-021-00962-2
24 ZHANG X， ZHAO L， ZHANG H， et al. The immunosuppressive microenvironment and immunotherapy in human glioblastoma［J］. Front Immunol， 2022，13：1003651. doi:10.3389/fimmu.2022.1003651
25 LIANG J， LI T， ZHAO J， et al. Current understanding of the human microbiome in glioma［J］. Front Oncol， 2022，12：781741. doi:10.3389/fonc.2022.781741
26 QIU Q， LIN Y， MA Y， et al. Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy［J］. Front Immunol， 2021，11：612202. doi:10.3389/fimmu.2020.612202
27 何宝坤. 基于肠道菌群发现用于治疗Treg缺失免疫缺陷病的新药［J］. 中国药理学与毒理学杂志， 2019，33（9）：750.
28 KAZMIERCZAK-SIEDLECKA K， MARANO L， MEROLA E， et al. Sodium butyrate in both prevention and supportive treatment of colorectal cancer［J］. Front Cell Infect Microbiol， 2022，12：1023806. doi:10.3389/fcimb.2022.1023806
29 Al-QADAMI G H， SECOMBE K R， SUBRAMANIAM C B， et al. Gut Microbiota-Derived Short-Chain Fatty Acids： Impact on Cancer Treatment Response and Toxicities［J］. Microorganisms， 2022，10（10）：2048. doi:10.3390/microorganisms10102048
30 MA X， MA L， WANG Z， et al. Clinical Features and Gut Microbial Alterations in Anti-leucine-rich Glioma-Inactivated 1 Encephalitis-A Pilot Study［J］. Front Neurol， 2020， 11：585977. doi:10.3389/fneur.2020.585977
31 XIONG R G， ZHOU D D， WU S X， et al. Health Benefits and Side Effects of Short-Chain Fatty Acids［J］. Foods， 2022，11（18）：2863. doi:10.3390/foods11182863
32 WANG L， LI S， FAN H， et al. Bifidobacterium lactis combined with Lactobacillus plantarum inhibit glioma growth in mice through modulating PI3K/AKT pathway and gut microbiota［J］. Front Microbiol， 2022，13：986837. doi:10.3389/fmicb.2022.986837
33 LI X C， WU B S， JIANG Y， et al. Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma［J］. Drug Des Devel Ther， 2021，15：1641-1652. doi:10.2147/dddt.s298261
34 JIANG H， ZENG W， ZHANG X， et al. The role of gut microbiota in patients with benign and malignant brain tumors： a pilot study［J］. Bioengineered， 2022，13（3）：7847-7859. doi:10.1080/21655979.2022.2049959
35 ?ANIEWSKI P， ILHAN Z E， HERBST-KRALOVETZ M M. The microbiome and gynaecological cancer development， prevention and therapy［J］. Nat Rev Urol， 2020，17（4）：232-250. doi:10.1038/s41585-020-0286-z
36 SI W， LIANG H， BUGNO J， et al. Lactobacillus rhamnosus GG induces cGAS/STING-dependent type I interferon and improves response to immune checkpoint blockade［J］. Gu， 2022，71（3）：521-533. doi:10.1136/gutjnl-2020-323426
Options
Outlines

/

〈 〉